Tag: Terran Biosciences - Psychedelic Alpha

Read more about the article Terran Biosciences announces exclusive licensing deal with Pierre Fabre for idazoxan; Terran completes key development milestones

Terran Biosciences announces exclusive licensing deal with Pierre Fabre for idazoxan; Terran completes key development milestones

Post published:June 2, 2023
Post category:Press Release

Read more about the article Terran Biosciences announces new breakthroughs in the chemistry of MDMA and its enantiomers and analogs, discovers new salts and polymorphs, publishes PCT application.

Terran Biosciences announces new breakthroughs in the chemistry of MDMA and its enantiomers and analogs, discovers new salts and polymorphs, publishes PCT application.

Post published:May 26, 2023
Post category:Press Release

Read more about the article Terran Biosciences discovers what may be the first new salts, co-crystals, and polymorphs of psilocybin in history, publishes PCT patent application, and files psilocybin Drug Master File (DMF) with FDA

Terran Biosciences discovers what may be the first new salts, co-crystals, and polymorphs of psilocybin in history, publishes PCT patent application, and files psilocybin Drug Master File (DMF) with FDA

Post published:May 19, 2023
Post category:Press Release

Read more about the article Terran Biosciences announces publication of four PCT patent applications covering breakthroughs in novel empathogens, including improved versions of methylone, ethylone, MDEA, MDAI, and MBDB

Terran Biosciences announces publication of four PCT patent applications covering breakthroughs in novel empathogens, including improved versions of methylone, ethylone, MDEA, MDAI, and MBDB

Post published:May 11, 2023
Post category:Press Release

Read more about the article Terran Biosciences announces publication of PCT patent application covering novel non-hallucinogenic psychoplastogens, including derivatives of DMT and ibogaine with improved pharmacokinetics and engagement at target receptors

Terran Biosciences announces publication of PCT patent application covering novel non-hallucinogenic psychoplastogens, including derivatives of DMT and ibogaine with improved pharmacokinetics and engagement at target receptors

Post published:May 9, 2023
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.